Mindfulness-Enhanced Dual-Task Training in PD-MCI
Mindfulness-Enhanced Cognitive-Motor Dual-Task Training Using Balance and Isokinetic Systems for Parkinson's Disease With Mild Cognitive Impairment: A Randomized Controlled Trial
1 other identifier
interventional
90
1 country
1
Brief Summary
The goal of this clinical trial is to learn if Mindfulness-Enhanced Dual-Task Training work to treat PD-MCI in adults. The main questions it aims to answer are: Does Mindfulness-Enhanced Dual-Task Training improve the cognitive or motor function of participants? Can the combination of Dual-Task Training and Mindfulness achieve better effects? Researchers will compare 3 groups (Dual-Task Training + Mindfulness, Dual-Task Training, and conventional motor task training) to see if Dual-Task Training and Mindfulness works to treat PD-MCI. Participants will: Receive treatment for 4 weeks Receive scale and instrument testing before and after treatment
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 9, 2025
CompletedFirst Posted
Study publicly available on registry
April 16, 2025
CompletedStudy Start
First participant enrolled
May 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 30, 2025
CompletedApril 16, 2025
April 1, 2025
3 months
April 9, 2025
April 9, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Montreal Cognitive Assessment (MoCA)
The Montreal Cognitive Assessment (MoCA) is a widely used neuropsychological tool for detecting mild cognitive impairment (MCI). It assesses multiple cognitive domains, including attention, executive function, memory, language, visuospatial ability, abstraction, calculation, and orientation. The total score is 30 points, with higher scores indicating better cognitive function.
From enrollment to the end of treatment at 4 weeks
Study Arms (3)
MDT group
EXPERIMENTALMindfulness-enhanced Dual-task Training
DT group
ACTIVE COMPARATORDual-task Training
ST group
ACTIVE COMPARATORSingle-task Training
Interventions
Participants perform physical exercises using the balance training system and isokinetic muscle strength training system while simultaneously completing cognitive tasks to improve motor-cognitive coordination. The training follows a task-segmentation approach: Balance Task Module: Participants perform dynamic balance training on the balance training system while engaging in cognitive tasks (e.g., digit span, arithmetic, or word fluency tasks). Strength Task Module: Participants conduct isokinetic strength training while performing corresponding cognitive tasks. Task difficulty is progressively adjusted based on participant performance.
Guided by a professional mindfulness instructor, participants engage in mindfulness meditation to enhance attention, emotional regulation, and cognitive readiness. The training includes breath awareness, body scan, and present-moment awareness, delivered through guided meditation.
Participants perform physical exercises using the balance training system and isokinetic muscle strength training system without any concurrent cognitive tasks. The training follows a task-segmentation approach, including dynamic balance training and isokinetic strength training to enhance motor function.
Participants remain seated in a quiet environment without engaging in mindfulness training or cognitive tasks.
Eligibility Criteria
You may qualify if:
- Age: Between 55 and 75 years.
- Disease Diagnosis: Clinically diagnosed with Idiopathic Parkinson's Disease (PD) according to the UK Parkinson's Disease Society Brain Bank Criteria.
- Disease Stage: Hoehn \& Yahr (H\&Y) stages 1 to 2.5.
- Cognitive Function: Montreal Cognitive Assessment (MoCA) score between 23 and 26, indicating mild cognitive impairment (MCI).
- Medication Stability: Stable doses of antiparkinsonian medications for at least 4 weeks prior to screening.
- Subjective Cognitive Complaints: Self-reported or informant-reported cognitive decline persisting for at least 6 months.
- Ambulatory Ability: Able to walk independently, with or without assistive devices.
- Sensory Abilities: Adequate vision and hearing to comply with study procedures.
- Informed Consent: Willingness to provide written informed consent and comply with study requirements.
You may not qualify if:
- Other Neurological Disorders: Presence of other neurological conditions that could affect cognitive function, such as Alzheimer's disease, stroke, or brain tumors.
- Psychiatric Conditions: Severe psychiatric disorders, including major depressive disorder or schizophrenia.
- Substance Abuse: Recent history of drug or alcohol abuse.
- Serious Medical Conditions: Uncontrolled hypertension, diabetes, heart disease, or other conditions that could interfere with study participation or outcomes.
- Severe Cognitive Impairment: Diagnosis of Parkinson's Disease Dementia (PDD).
- Other Factors Affecting Cognition: Recent head trauma, uncontrolled thyroid dysfunction, vitamin B12 deficiency, or other conditions known to affect cognitive function.
- Deep Brain Stimulation (DBS): History of DBS treatment. Participation in Other Clinical Trials: Participation in another clinical trial that could interfere with this study within the last 3 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nanjing Mingzhou Rehabilitation Hospital
Nanjing, Jiangsu, 210046, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- technician in charge
Study Record Dates
First Submitted
April 9, 2025
First Posted
April 16, 2025
Study Start
May 1, 2025
Primary Completion
July 30, 2025
Study Completion
July 30, 2025
Last Updated
April 16, 2025
Record last verified: 2025-04